Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate

On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)’s Phase 3 survey (NCT05907122) saw an update. The survey investigating ABP 206, a biosimilar campaigner for Opdivo (nivolumab), has officially reached Completed status. The proceedings enrolled 256 subjects with resected signifier III oregon IV melanoma to show pharmacokinetic similarity and objective efficacy implicit a 12-month adjuvant period. The superior completion was reached successful March 2025, and last updates were posted successful precocious February 2026. Data is apt being analyzed to enactment regulatory filings. If successful, ABP 206 could found Amgen Inc. (NASDAQ:AMGN) arsenic a cardinal supplier of lower-cost immunotherapy for precocious melanoma.

On February 19, 2026, Wells Fargo raised the terms people connected Amgen Inc. (NASDAQ:AMGN) from $325 to $375 portion maintaining an Equal Weight rating. The steadfast is revising its valuation exemplary to incorporated 10-K fiscal updates. It besides noted that it is assigning caller terms targets to bespeak the further worth of its Phase 3 pipeline assets.

Founded successful 1980, Amgen Inc. (NASDAQ:AMGN) is simply a starring planetary biotechnology institution focused connected discovering, developing, and manufacturing innovative quality therapeutics for superior illnesses. Its office is successful California.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 13 High-Quality S&P 500 Financial Stocks According to Hedge Funds

Disclosure. None. Follow Insider Monkey connected Google News.